Literature DB >> 2383752

Hyperthermic isolated perfusion with melphalan in the treatment of advanced malignant melanoma of the lower limb.

A I Skene1, A S Bulman, T R Williams, J M Thomas, G Westbury.   

Abstract

A retrospective study of 91 patients with malignant melanoma treated by lower limb isolated hyperthermic regional perfusion was performed. Objective response in patients with evaluable disease was 78 per cent. The role of perfusion as primary treatment of large melanomas of the foot is confirmed and recommended. Control of locoregional disease and limb salvage remains a valuable and attainable therapeutic goal using this technique.

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2383752     DOI： 10.1002/bjs.1800770716

Source DB:  PubMed          Journal:  Br J Surg        ISSN： 0007-1323            Impact factor:   6.939


  10 in total

1.  Current trends in regional therapy for melanoma: lessons learned from 225 regional chemotherapy treatments between 1995 and 2010 at a single institution.

Authors:  Amanda K Raymond; Georgia M Beasley; Gloria Broadwater; Christina K Augustine; James C Padussis; Ryan Turley; Bercedis Peterson; Hilliard Seigler; Scott K Pruitt; Douglas S Tyler
Journal:  J Am Coll Surg       Date:  2011-04-13       Impact factor: 6.113

2.  Prospective multicenter phase II trial of systemic ADH-1 in combination with melphalan via isolated limb infusion in patients with advanced extremity melanoma.

Authors:  Georgia M Beasley; Jonathan C Riboh; Christina K Augustine; Jonathan S Zager; Steven N Hochwald; Stephen R Grobmyer; Bercedis Peterson; Richard Royal; Merrick I Ross; Douglas S Tyler
Journal:  J Clin Oncol       Date:  2011-02-22       Impact factor: 44.544

Review 3.  Exercising in environmental extremes : a greater threat to immune function?

Authors:  Neil P Walsh; Martin Whitham
Journal:  Sports Med       Date:  2006       Impact factor: 11.136

4.  A phase I multi-institutional study of systemic sorafenib in conjunction with regional melphalan for in-transit melanoma of the extremity.

Authors:  G M Beasley; A P Coleman; A Raymond; G Sanders; M A Selim; B L Peterson; M S Brady; M A Davies; C Augustine; D S Tyler
Journal:  Ann Surg Oncol       Date:  2012-05-02       Impact factor: 5.344

Review 5.  Isolated limb perfusion for extremity soft-tissue sarcomas, in-transit metastases, and other unresectable tumors: credits, debits, and future perspectives.

Authors:  A M Eggermont; T L ten Hagen
Journal:  Curr Oncol Rep       Date:  2001-07       Impact factor: 5.075

6.  Optimizing melphalan pharmacokinetics in regional melanoma therapy: does correcting for ideal body weight alter regional response or toxicity?

Authors:  N McMahon; T Y Cheng; G M Beasley; I Spasojevic; W Petros; C K Augustine; P Zipfel; J C Padussis; G Sanders; Douglas S Tyler
Journal:  Ann Surg Oncol       Date:  2009-01-30       Impact factor: 5.344

7.  Predicting disease progression after regional therapy for in-transit melanoma.

Authors:  Michael E Lidsky; Ryan S Turley; Georgia M Beasley; Ketan Sharma; Douglas S Tyler
Journal:  JAMA Surg       Date:  2013-06       Impact factor: 14.766

8.  Isolation perfusion in extracorporeal circulation with interleukin-2 and lymphokine-activated killer cells in the treatment of in-transit metastases from limb cutaneous melanoma.

Authors:  M Vaglini; F Belli; M Santinami; F Arienti; G Parmiani; L Persiani; N Santoro; M Grazia Inglese; F D'Elia; N Cascinelli
Journal:  Ann Surg Oncol       Date:  1995-01       Impact factor: 5.344

9.  Hyperthermic isolated limb perfusion for malignant melanoma: response and survival.

Authors:  P J Bryant; G A Balderson; P Mead; W S Egerton
Journal:  World J Surg       Date:  1995 May-Jun       Impact factor: 3.352

10.  Toxicity and morbility after isolated lower limb perfusion in 242 chemo-hyperthermal treatments for cutaneous melanoma: the experience of the Tuscan Reference Centre.

Authors:  Marcello Pace; Riccardo Gattai; Maria Matteini; Erminia Macera Mascitelli; Paolo Bechi
Journal:  J Exp Clin Cancer Res       Date:  2008-11-12
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.